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Abstract
Calcitonin gene-related peptide (CGRP) is a neuropeptide with a pivotal role in the pathophysiology of migraine.
Blockade of CGRP is a new therapeutic target for patients with migraine. CGRP and its receptors are distributed not
only in the central and peripheral nervous system but also in the cardiovascular system, both in blood vessels and
in the heart. We reviewed the current evidence on the role of CGRP in the cardiovascular system in order to
understand the possible short- and long-term effect of CGRP blockade with monoclonal antibodies in migraineurs.
In physiological conditions, CGRP has important vasodilating effects and is thought to protect organs from
ischemia. Despite the aforementioned cardiovascular implication, preventive treatment with CGRP antibodies has
shown no relevant cardiovascular side effects. Results from long-term trials and from real life are now needed.
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Introduction
Migraine is one of the leading chronic neurological disor-
ders, considered among the top five causes of long-term
disability and affecting 15% of the population, mainly
women [1, 2]. Treatments for migraine can be divided into
abortive and prophylactic therapy. Calcitonin gene-related
peptide (CGRP) blockade has emerged as a therapeutic tar-
get for migraine. CGRP is a neuropeptide released from
perivascular nerve fibers after trigeminal nerve activation
performing a pivotal role in the pathophysiology of mi-
graine [3, 4]. In recent years, monoclonal antibodies against
CGRP and its receptors have been developed and tested in
clinical trials involving migraine patients. The site of action
of these antibodies is still debated. Because they are large
molecules, they have limited potential to pass the
blood-brain barrier (BBB) and may act at the peripheral
level. However, some studies have shown that brain struc-
tures involved in the pathophysiology of migraine (e.g. tri-
geminal ganglion and the paraventricular structures within
the brain stem) are not fully protected by the BBB [5–7],
hence effective migraine treatment drugs need not to pass
through the BBB. Furthermore, the antimigraine action site
may reside in areas not protected by the BBB such as the
intra- and extracranial vessels, dural mast cells, and the tri-
geminal system [3]. Interestingly, CGRP receptors are lo-
cated not only in the central and peripheral nervous system
but also in the cardiovascular system including blood ves-
sels and the heart [8]. CGRP acts as a very potent vasodila-
tor and plays an important role in regulating vascular
resistance and regional organ blood flow in physiological
and also during pathological conditions like cerebral or car-
diac ischemia [7, 9–11]. We reviewed the current evidence
on the role of CGRP in the cardiovascular system to under-
stand the possible short- and long-term effect of CGRP
blockade with monoclonal antibodies in migraineurs.
* Correspondence: valentina.favoni2@unibo.it
†Valentina Favoni, Luca Giani, Linda Al-Hassany, Gian Maria Asioli, Calogera
Butera, Irene de Boer, Martina Guglielmetti, Chrysoula Koniari, Theodoros
Mavridis, Marge Vaikjärv, Iris Verhagen, Angela Verzina, Bart Zick, Paolo
Martelletti and Simona Sacco contributed equally to this work.
1Department of Biomedical and Neuromotor Sciences, University of Bologna,
Bologna, Italy
2IRCCS Istituto delle Scienze Neurologiche di Bologna, Via Altura, 3 Pad. G,
40139 Bologna, Italy
Full list of author information is available at the end of the article
The Journal of Headache
                           and Pain
© The Author(s). 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made.
Favoni et al. The Journal of Headache and Pain           (2019) 20:27 
https://doi.org/10.1186/s10194-019-0979-y
Methods of review
Two independent reviewers conducted an independent
search on PubMed on July 20th, 2018 using the search
terms “cgrp” AND “cardiovascular system” OR “cardio-
vascular” AND “system”. This search generated 1585 ab-
stracts, which were reviewed independently, and articles
were selected on the basis of relevance to the present
topic. Discrepancies between investigators were
rechecked and, if necessary, discussed with a third inves-
tigator until consensus was achieved. Every author added
additional papers when needed in their respective sec-
tion. The final reference list was generated on the basis
of originality and relevance to the topic of this Review.
Calcitonin gene-related peptide and CGRP receptors
CGRP, a peptide with 37 amino acid residues, exists in
humans in two isoforms, α and βCGRP, otherwise
known as CGRP I and II. Alternative splicing of the
CACL1 gene (calcitonin gene) produces, most promin-
ently in the central and peripheral nervous system,
αCGRP [12, 13]. Transcription of the CACLII gene leads
to βCGRP, most abundantly found in the enteric sensory
system [12, 13]. αCGRP and βCGRP share > 90% hom-
ology in humans (with only three amino acids being dif-
ferent) [14]. Therefore, it is logical that their biological
activity is similar. CGRP is expressed in the peripheral
nervous system in thin unmyelinated C fibers, and at
numerous sites in the central nervous system [4, 15–
17].The synthesis and release of CGRP can be triggered
by activation of the transient receptor potential vanilloid
subfamily member 1 (TRPV1). One of the ligands of
TRPV1, capsaicin, was first used to demonstrate the re-
lease of CGRP from sensory neurons [10]. However, the
synthesis and release of CGRP is mediated by many fac-
tors, which are still being investigated.
CGRP acts by activating multiple receptors [18–20]. The
functional CGRP receptor consists of three components:
calcitonin-like receptor (CLR), receptor component protein
(RCP) which defines the G-protein to which the receptor
binds, and receptor activity-modifying protein 1 (RAMP1)
[19–21]. RCP links the receptor to an intracellular C
protein-mediated signaling pathway, which increases cyclic
adenosine monophosphate (cAMP) levels [22]. For updated
classification and nomenclature of calcitonin/CGRP family
of peptides and receptors see Table 1. CGRP receptors are
also present on the smooth muscle cells of human cranial
and coronary arteries [9, 23]. It remains unclear if there is a
difference in the expression of CGRP receptors between
cranial and coronary arteries, but functional studies suggest
a higher expression of CGRP receptors in cranial arteries.
Receptor components of CGRP have also been identified in
the trigeminal ganglion, cerebral cortex, hippocampus, thal-
amus, hypothalamus, brainstem, spinal cord and cerebel-
lum [24–26]. As such, CGRP probably has both neural and
vascular actions.
Endothelial dysfunction and CGRP in migraineurs
Various vascular mechanisms have been described in
order to explain the role of CGRP in vasodilation of per-
ipheral vascular beds. The presence of an NO- and
endothelium-independent pathway, which leads to vas-
cular relaxation, has been observed in smooth muscle
cells of most tissues [27, 28]. However, CGRP also has
the capability to stimulate the production of NO by act-
ing via a receptor located on the endothelium. This
endothelium-dependent relaxation pathway results in an
accumulation of cAMP and production of NO through
endothelial protein kinase A/endothelial NO Synthase
(PKA/eNOS) signaling. Eventually, NO diffuses into ad-
jacent smooth muscle cells and activates guanylate cy-
clase. This finally leads to the production of cGMP and
relaxation of vessels [11, 28, 29]. The role of endothe-
lium in migraine pathophysiology is still debated. Some
studies indicate that migraineurs have an impaired
Table 1 Current classification of human calcitonin-family receptors, subunit composition and respective ligands
CGRP Calcitonin Gene-Related Peptide, AM Adrenomedullin, AMY Amylin, CTR Calcitonin Receptor, CLR Calcitonin receptor-like receptor, RAMP receptor
activity-modifying proteins, AM2/IMD Adrenomedullin 2/Intermedin
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arterial and endothelial function as compared to
non-migraineurs [30]. On the contrary, a recent study
suggested that the contribution of endothelium to
CGRP-induced vasodilation may not be significant [31].
In fact, cutaneous microvascular sensitivity to endothe-
lial and non-endothelial donors including CGRP showed
no difference between a group of patients with migraine
compared to controls [32]. It has been speculated that
alterations at the endothelial level may contribute to the
increased risk (approximately 50%) of several cardiovas-
cular diseases such as ischemic and hemorrhagic stroke,
angina and myocardial infarction, which has been ob-
served in several studies that compared migraineurs
(with aura) to non-migraineurs [33–38].
Physiological and pathological influence of CGRP on the
cardiovascular system
CGRP release induces relaxation of smooth muscle cells
due to an increase in cAMP and leads to activation of
protein kinase A, which phosphorylates and opens po-
tassium channels [39, 40]. In blood vessels, CGRP acts
as an extremely potent vasodilator when compared to
several known vasodilators such as histamine, prosta-
glandin E2 and substance P [41]. Even so, CGRP seems
to have no pivotal role in the physiological regulation of
systemic blood pressure. For instance, blocking CGRP
does not affect systemic blood pressure in healthy volun-
teers [42]. In the heart, CGRP is localized in sensory
nerve fibers and around peripheral arteries [9]. There
are specific binding sites for CGRP linked to stimulation
of adenylate cyclase activity more concentrated in the
atrium [43]. In both rats and humans, in addition to its
vasodilator effect, intravenous CGRP administration has
been shown to cause positive inotropic and chronotropic
effects on the heart [44–47]. In physiological conditions,
CGRP might act on a more local level, regulating vascu-
lar responsiveness and protecting organs from injury.
Thus, CGRP may have a cardiovascular protective role.
In pathophysiological situations, like hypertension, con-
flicting observations have been made. Both decreased,
increased and unchanged plasma levels of CGRP have
been observed in patients with essential hypertension
[48, 49]. While CGRP does not seem to be involved in
the physiological regulation of blood pressure, it has a
protective role against the development of hypertension.
It exerts its action mainly directly on smooth muscle
cells in the vessel wall, most prominently in the micro-
vasculature, which is responsible for the majority of the
peripheral vascular resistance and thus, the blood pres-
sure [9, 50].
Moreover, CGRP given intravenously to patients with
congestive heart failure improved myocardial contractil-
ity without any consistent change in arterial pressure or
heart rate [51]. CGRP causes beneficial effects on
physiological cardiac hypertrophy helping the heart to
distinguish physiological, exercise-induced from patho-
logical stresses [52].
In addition, CGRP may play an important role in me-
diation of ischemic preconditioning, the phenomenon in
which a tissue is rendered resistant to the deleterious ef-
fects of prolonged ischemia. Capsaicin, which evokes
CGRP release from sensory nerves, is reported to pro-
tect against myocardial injury by ischemia-reperfusion in
the isolated perfused rat heart [53]. Moreover, pretreat-
ment with CGRP for 5 min produces a significant pro-
tective effect on the ischemic myocardium, as shown by
the enhanced post-ischemic myocardial function, the re-
duced incidence of ventricular arrhythmia, and the at-
tenuated release of creatine phosphate kinase [54]. Some
studies have also suggested that the protective role of
CGRP against ischemia may be due to induced vasodila-
tion [55]. In the setting of brain ischemia, it might re-
duce the extent of the infarct zone [56], while in the
case of subarachnoid hemorrhage, there is evidence that
CGRP is protective against cerebral vasospasm [57–59].
CGRP might be protective also in the setting of chronic
cerebrovascular disease (as induced by bilateral carotid
stenosis) and the subsequent neuronal injury and cogni-
tive impairment [56].
Sex differences and CGRP pathophysiology
CGRP plasma levels are higher in women than in men
[60]. Cardiovascular benefits of CGRP, such as vasodila-
tory and hypotensive effects on the arteries [61] and the
positive inotropic effects on the myocardium are strongly
influenced by fluctuations in female sex hormone levels
[62]. Furthermore, sex hormone receptors are found in
the trigeminovascular and cardiovascular system and,
therefore, it is likely that there is an interaction between
female sex hormones and CGRP, but the exact mechanism
is still not fully understood [63, 64]. In animal models, fe-
males had higher CGRP levels in the medulla and lower
expression of CLR, RAMP1 and RCP-encoding mRNA in
tissues, compared to males, suggesting that CGRP recep-
tor synthesis, expression or release in the trigeminovascu-
lar system may be regulated by fluctuating female sex
hormones. Numerous animal and human studies have
shown that cyclic fluctuations of ovarian hormones
(mainly estrogen) modulate CGRP both in peripheral and
central nervous system [65–67]. It is, therefore, reasonable
to think that females, in particular, are sensitive to thera-
peutic effects of CGRP blockade, but also to adverse
events. In clinical practice, it would be useful to know
whether female migraineurs have an additional higher car-
diovascular risk if they are prescribed CGRP monoclonal
antibodies for the treatment of migraine. Future studies
should assess possible sex differences in the benefits and
harms of drugs acting on the CGRP and its receptor.
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Blocking CGRP
The blockade of the CGRP system has been obtained by
different molecules: non-peptide CGRP antagonists also
known as “gepants” (olcegepant, telcagepant, ubrogepant,
atogepant), monoclonal antibodies against CGRP (eptine-
zumab, fremanezumab, galcanezumab) and monoclonal
antibodies against CGRP receptor (erenumab).
Gepants have demonstrated efficacy in relieving mi-
graine in clinical trials and do not cause direct vasocon-
striction. However, olcegepant had to be administered
intravenously due to its low oral bioavailability [68, 69].
Encouraged by the efficacy of blocking CGRP for the
treatment of migraine, monoclonal antibodies able to
block either CGRP or its receptor were developed.
CGRP antibodies have a slower onset of action com-
pared with the CGRP receptor antagonists, which is con-
sistent with the idea of a slower penetration into the
interstitial space of the vascular smooth muscle tissue.
The inhibition is evident one week after dosing [70].
Moreover, CGRP antibodies might scavenge CGRP for
up to 1.5 months [7].
Short-term effects of blocking CGRP
The cardiovascular safety of short-term CGRP blockade
has been widely explored for both CGRP antagonists
and for monoclonal antibodies. In animal models, sev-
eral studies conducted on non-peptidic CGRP-R antago-
nists (olcegepant) evidenced that short-term blockade of
CGRP have no effects on hemodynamic parameters such
as heart rate, blood pressure, cardiac output, coronary
flow or severity of ischemia were observed in different
animal species [71–73]. CGRP antagonism is safe in
healthy volunteers; a study demonstrated that the ad-
ministration of telcagepant at supra-therapeutic dosage
did not induce vasoconstriction both in peripheral and
central vascular beds in healthy men [74]. Moreover, this
drug did not influence treadmill-exercise-time in pa-
tients with stable angina [75].
Clinical trials of single-doses of oral telcagepant admin-
istered for acute treatment of migraine showed a total ab-
sence of cardiovascular side effects in migraine patients
[76, 77]. Only minor adverse events were registered (dry
mouth, somnolence, dizziness, nausea, fatigue) [78].
Since the half-life of monoclonal antibodies is longer
(21–50 days) [79] than that of non-peptidic CGRP antago-
nists, the blockade of CGRP has a longer duration. In rats
CGRP blocking antibodies inhibit the neurogenic vaso-
dilation, confirming the role of these molecules in treating
migraine, but no effect on heart rate and arterial blood
pressure was observed [70]. Similar results were obtained
using fremanezumab in monkeys, where the effect of sin-
gle or multiple (once weekly for 14 weeks) injections on
cardiovascular parameters were evaluated. No meaningful
modifications of ECG parameters, heart rate, and systolic
blood pressure were observed in both situations [80]. In
another trial, healthy women over 40 years old (mean age
56 years) were monitored for 24 weeks after administra-
tion of a single dose of fremanezumab at different dosages.
No changes in ECG parameters, nor heart rate or blood
pressure were registered [81].
Safety and tolerability data from clinical trials are en-
couraging for the anti-CGRP monoclonal antibodies for
the treatment of both episodic and chronic migraine. All
phase II and phase III clinical trials completed so far for
the four developed monoclonal antibodies did not show
any safety problem concerning the cardiovascular system
[82, 83]. It must be noted that the patients recruited for
clinical trials were young (age range 18–65, with a mean
of about 40 years) usually without any significant cardio-
vascular disease. Therefore, the safety profile of this class
of drugs in high-risk patients has to be specifically ad-
dressed. A randomized, double-blind placebo-controlled
study was performed for studying the cardiovascular ef-
fect of erenumab in patients with stable angina. In par-
ticular, the investigators evaluated the impact of a dose
of the drug (iv infusion of 140 mg) on exercise time dur-
ing a treadmill test. There was no decrease in treadmill
test, so they concluded that the inhibition of CGRP re-
ceptor does not worsen myocardial ischemia [84]. One
major criticism about this study regards the population
selected, which was composed of non-migraineurs; data
indicate that migraineurs are at risk for cardiovascular
events [34, 36]. Thus, safety of anti-CGRP monoclonal
antibodies in migraineurs may be different from that of
the general population. Additionally, in that study most
patients (80%) were males, while migraine is more
prevalent in women. As previously discussed, sex hor-
mones influence the activity of CGRP on the vascular
tone and female migraineurs are at increased risk of
myocardial infarction [85], possibly exposing them to a
specific sensitivity to CGRP blockade [77].
Long-term effects of blocking CGRP
Pre-registration trials are mostly limited to a maximum of
6months. Considering the role of CGRP in cardiovascular
physiology and in the pathophysiology, this time frame
could not be enough to exclude effects of blockade in the
long run. There is just one published article about a trial
longer than 6months using anti-CGRP drugs [86]. The in-
terim analysis after one year of open label extension of an
erenumab trial (EudraCT 2012–005331-90, NCT01952574)
among 383 subjects exposed for a median of 575 days re-
ported one case of death in a 52-year-old man with
pre-existing cardiovascular risk factors (hypertension,
hypercholesterolemia, obesity, familial history) and
post-mortem evidence of severe coronary atherosclerosis
and use of sympathomimetics. A case of transient
exercise-induced myocardial ischemia during a treadmill
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test was confounded by sumatriptan intake 4 h prior to the
event [86]. Considering the presence of confounding fac-
tors, these adverse events may be not related to the treat-
ment. However, a limitation of the study is the lack of a
placebo group, which makes it difficult to differentiate
spontaneously occurring adverse events from adverse
events due to erenumab.
In all short- and long-term studies published, investi-
gators have not observed any hypertensive effect of
anti-CGRP drugs, nor were any negative effects observed
regarding the development or aggravation of cardiac fail-
ure, although this last issue was not specifically ad-
dressed, there was no specific monitoring, and it is not
clear if any patient with heart failure was treated. More-
over, the time frame might be not enough to observe a
clinical effect of organ remodeling.
Regarding the cerebrovascular risk of anti-CGRP
drugs, no safety issues have emerged from all the trials
completed so far.
Conclusions
In conclusion, CGRP plays an important role in migraine
but also in physiological and pathological cardiovascular
conditions. We can speculate that CGRP may act as a
link between the brain and the heart. Data emerging
from trials with CGRP antibodies suggest that this spe-
cific blockade of the CGRP pathway is a safe treatment.
To our knowledge, no serious adverse events have been
reported since approval of anti-CGRP monoclonal anti-
bodies for migraine treatment in May 2018. However, re-
sults from long-term trials and real life are particularly
awaited in order confirm these encouraging data on the
long-term safety of the new migraine preventive drugs.
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